When the platelet count is higher than normal after thrombocytopenia treatment, platelet-boosting drugs are immediately discontinued, and routine blood tests are regularly repeated to observe changes in platelet count. As the platelet count rises, blood viscosity will gradually increase, leading to a higher risk of thrombotic diseases such as cerebral infarction. Patients with thrombocytopenia who have higher than normal platelet counts after treatment need to stop taking platelet-raising drugs (e.g., recombinant human thrombopoietin injection, Lycopodium tablets, dexamethasone, prednisone, etc.) immediately, or else their platelet counts may continue to rise, with a consequent increase in the risk of thrombotic disorders. 2. However, platelet count may decrease again after stopping the platelet-boosting drugs, so it is necessary to review the blood routine regularly to dynamically observe the change of platelet count, and when the platelet count is lower than the normal range, a platelet-boosting treatment plan can be formulated according to the patient’s specific condition. It is recommended that the patient should consult the hematology department in a timely manner, and individualized treatment plan should be formulated after the specialist evaluates the patient’s condition.